Targets › ITGA2B
7 programs from 7 companies in 12 trials: 6 Phase 3, 3 Phase 2, 2 Phase 4, 1 Phase 1; Neurology, Cardiovascular, Other; next expected readout Dec 2026.
Integrin alpha-IIb/beta-3 (ITGA2B:ITGB3) is a receptor for fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin and vitronectin. It recognizes the sequence R-G-D in a wide array of ligands. (UniProt, P08514)
Open in Phaseline: the race on ITGA2B, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Beijing Anzhen Hospital | Tirofiban Integrin alpha-IIb/beta-3 inhibitor | ITGB3, ITGA2B | Phase 4 | Acute Ischemic Stroke | Dec 2026 |
| Second Affiliated Hospital of Soochow University | Tirofiban Integrin alpha-IIb/beta-3 inhibitor | ITGB3, ITGA2B | Phase 4 | Mild Stroke | Feb 2027 |
| Beijing Tiantan Hospital | Y-4 tablets Integrin alpha-IIb/beta-3 inhibitor | PDE3A, ITGB3, ITGA2B, IL1R1 | Phase 3 | Ischemic Stroke, Acute; Aneurysmal Subarachnoid Hemorrhage; Acute Ischemic Stroke; Stroke Acute … | Dec 2026 |
| General Hospital of Shenyang Military Region | Tirofiban Integrin alpha-IIb/beta-3 inhibitor | ITGB3, ITGA2B | Phase 3 | Stroke, Ischemic | Sep 2027 |
| Weifang Medical University | Tirofiban Integrin alpha-IIb/beta-3 inhibitor | ITGB3, ITGA2B | Phase 3 | Stroke, Acute | Feb 2029 |
| Second Affiliated Hospital of Guangxi Medical University | Tirofiban Hydrochloride Integrin alpha-IIb/beta-3 inhibitor | ITGB3, ITGA2B | Phase 3 | Acute Ischemic Stroke | – |
| CeleCor Therapeutics | Zalunfiban Integrin alpha-IIb/beta-3 inhibitor | ITGB3, ITGA2B | Phase 3 | ST-elevation Myocardial Infarction (STEMI) | – |
Acute Ischemic Stroke (3) Stroke Acute (2) ST-elevation Myocardial Infarction (STEMI) (1) Mild Stroke (1) Stroke, Ischemic (1) Ischemic Stroke, Acute (1) Aneurysmal Subarachnoid Hemorrhage (1) Healthy Adult Male and Female Volunteers (1) Stroke, Acute (1)
small molecule (7)
CeleCor Therapeutics (1) Second Affiliated Hospital of Soochow University (1) General Hospital of Shenyang Military Region (1) Beijing Tiantan Hospital (1) Second Affiliated Hospital of Guangxi Medical University (1) Beijing Anzhen Hospital (1) Weifang Medical University (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.